Skip to main content
. 2019 Dec 10;14(12):e0220265. doi: 10.1371/journal.pone.0220265

Fig 1. National and regional prevalence of ESBL phenotypes, levofloxacin- and trimethoprim-sulfamethoxazole-resistant phenotypes among 1831 isolates of E. coli from UTIs in the USA in 2017.

Fig 1

ESBL = extended spectrum β-lactamase, LEVO-R = levofloxacin-resistant, TMP-SMX-R = trimethoprim-sulfamethoxazole-resistant.